| 2026-08-14 | Deck | Celldex Therapeutics Corporate Presentation |
| 2026-08-06 | Press release | Press release · Q2 2026 · Aug 2026 |
| 2026-08-06 | Press release | Celldex Reports Second Quarter Financial Results and Provides Corporate Update · 2026 |
| 2026-08-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-06 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-21 | Press release | Press release · Jul 2026 |
| 2026-07-21 | Press release | Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis |
| 2026-07-15 | Press release | Press release · Jul 2026 |
| 2026-07-15 | Press release | Celldex Announces Planned Transition of Chief Financial Officer |
| 2026-07-15 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-26 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-14 | Press release | Press release · Jun 2026 |
| 2026-06-14 | Press release | Press release · Jun 2026 |
| 2026-06-14 | Press release | Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy |
| 2026-06-14 | Press release | Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Pati |
| 2026-06-10 | Press release | Press release · Jun 2026 |
| 2026-06-10 | Press release | Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 Europea |
| 2026-05-07 | Press release | Press release · Q1 2026 · May 2026 |
| 2026-05-07 | Press release | Celldex Reports First Quarter Financial Results and Provides Corporate Update · 2026 |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-29 | Proxy | Definitive proxy statement |
| 2026-04-13 | Press release | Press release · Apr 2026 |
| 2026-04-13 | Press release | Celldex to Present at Upcoming Investor Conference |
| 2026-04-06 | Press release | Press release · Apr 2026 |
| 2026-04-06 | Press release | Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to P |
| 2026-04-02 | 8-K | Form 8-K, Item 1.01 |
| 2026-04-01 | Press release | Press release · Apr 2026 |
| 2026-04-01 | Press release | Press release · Apr 2026 |
| 2026-04-01 | Press release | Celldex Announces Proposed Public Offering of Common Stock |
| 2026-04-01 | Press release | Celldex Announces Pricing of $300 Million Public Offering of Common Stock |
| 2026-03-27 | Press release | Press release · Mar 2026 |
| 2026-03-27 | Press release | Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Der |
| 2026-03-01 | Press release | Press release · Mar 2026 |
| 2026-03-01 | Press release | Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Expos |
| 2026-02-27 | Press release | Press release · Feb 2026 |
| 2026-02-27 | Press release | Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (C |
| 2026-02-25 | Press release | Press release · Q4 2025 · Feb 2026 |
| 2026-02-25 | Press release | Press release · Feb 2026 |
| 2026-02-25 | Press release | Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update |